Effect of Qiming granule on retinal vessel oxygen saturation in patients with non-proliferative diabetic retinopathy

doi:10.3877/cma.j.issn.2095-2007.2020.06.003

Abstract

Abstract:

Objective

The aim of this study was to explore the effect of Qiming granule on retinal microcirculation in patients with non-proliferative diabetic retinopathy (DR).

Methods

From October 2016 to May 2017, 16 eligible patients (31 eyes) with non-proliferative DR from the Department of Ophthalmology affiliated to Hospital of Chengdu University of Traditional Chinese Medicine were investigated. Among of them, including 12 male cases (23 eyes) and 4 female cases (8 eyes) with the average age (62.5±8.3) years-old. To observe and record the changes in visual acuity, fundus hemorrhage area, glycosylated hemoglobin (HbA1c), retinal blood oxygen saturation and vessel diameter, and the mean ocular perfusion pressure before and after treatment for 12 weeks with Qiming granule. The HbA1c, fundus hemorrhage area, retinal blood oxygen saturation and vessel diameter, and the mean ocular perfusion pressure before and after treatment were expressed by mean±standard deviation. The paired t testing was used to compare within groups. Visual acuity comparison adopts single factor repeated measures analysis of variance.

Results

The duration of diabetes in the subjects was 1 to 30 years, with an average of (13.75±9.31) years. Before and after treatment for 4, 8, 12 weeks, visual acuity were (73.81±7.90), (73.97±8.53), (74.74±7.29), and (76.26±6.80), respectively. After treatment for 12 weeks, visual acuity had a tendency to improve. After analysis of variance, the difference in visual acuity was not statistically significant before and after treatment (F=2.162, P>0.05). Before treatment, systolic blood pressure, diastolic blood pressure, the intraocular pressure, the mean ocular perfusion pressure were (129.13±8.36) mmHg (1 mmHg=0.133 kPa), (74.44±6.92) mmHg, (15.58±2.90) mmHg, (46.06±4.90) mmHg, respectively. After treatment for 12 weeks, those were (126.94±10.11) mmHg, (70.81±8.83) mmHg, (14.54±1.84) mmHg, (45.43±4.80) mmHg, respectively. After analysis of paired t testing, there were non-significant difference in systolic blood pressure, diastolic blood pressure, the intraocular pressure before and after the treatment (t=0.797, 1.383, 1.853, 0.538; P>0.05). Before treatment, HbAlc, the mean values of retinal vein blood oxygen saturation, the mean values of the difference in arterial and venous oxygen saturation were (7.68±1.17)%, (63.18±7.07)%, (37.93±6.50)%, respectively. After treatment for 12 weeks, those were (6.73±1.49)%, (60.16±5.21)%, (39.93±4.04)%, respectively. After analysis of paired t testing, there were significant difference in HbAlc, the mean values of retinal vein blood oxygen saturation, the mean values of the difference in arterial and venous oxygen saturation before and after the treatment (t=2.611, 2.482, -2.259; P<0.05). Before treatment, the fundus hemorrhage area and the mean values of retinal artery blood oxygen saturation (4713.70±8082.42) pixels, (101.12±6.54)%, respectively. After treatment for 12 weeks, those were (3776.66±6553.91) pixels, (100.09±5.95)%, respectively. After analysis of paired t testing, there were non-significant difference in the fundus hemorrhage area and the mean values of retinal artery blood oxygen saturation before and after the treatment (t= 1.571, 1.047; P>0.05).

Conclusions

Qiming granule could reduce retinal venous oxygen saturation and increase the mean values of the difference in arterial and venous oxygen saturation in patients with non-proliferative DR.

Key words: Diabetic retinopathy, Qiming granule, Retinal oxygen saturation

Jian Huo, Junguo Duan, Keyu Zhu, Jialing Ai, Jiaqing Sui. Effect of Qiming granule on retinal vessel oxygen saturation in patients with non-proliferative diabetic retinopathy[J]. Chinese Journal of Ophthalmologic Medicine(Electronic Edition), 2020, 10(06): 333-338.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhykyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2007.2020.06.003

https://zhykyxzz.cma-cmc.com.cn/EN/Y2020/V10/I06/333

Figures/Tables 2

References 37

[1]	Chistiakov DA. Diabetic retinopathy: Pathogenic mechanisms and current treatments[J]. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 2011, 5(3): 165-172.
[2]	Hardarson SH, Stefánsson E. Retinal oxygen saturation is altered in diabetic retinopathy[J]. Br J Ophthalmol, 2012, 96(4): 560-563.
[3]	Hammer M, Vilser W, Riemer T, et al. Diabetic patients with retinopathy show increased retinal venous oxygen saturation[J]. Graefes Arch Clin Exp Ophthalmol, 2009, 247(8): 1025-1030.
[4]	Kifley A, Wang JJ, Cugati S, et al. Retinal vascular caliber, diabetes, and retinopathy[J]. Am J Ophthalmol, 2007, 143(6): 1024-1026.
[5]	Dong YM, Lin LL, Yan H, et al. Shifts in retinal vessel diameter and oxygensaturation in Chinese type 2 diabetes mellitus patients[J]. BMC Ophthalmology, 2016, 16: 43.
[6]	Luo XX, Duan JG, Liao PZ, et al. Effect of qiming granule on retinal blood circulation of diabetic retinopathy: a multicenter clinical trial[J]. Chin J of Integr Med, 2009, 15(5): 384-388.
[7]	李科军，赵智华，樊芳，等. 芪明颗粒对糖尿病患者脉络膜循环的影响[J]. 国际眼科杂志，2016，16(3)：499-501.
[8]	中华医学会眼科学会眼底病学组. 我国糖尿病视网膜病变临床诊疗指南(2014年)[J]. 中华眼科杂志，2014，50(11)：851-865.
[9]	Pournaras CJ, Rungger-Brandle E, Riva CE, et al. Regulation of retinal blood flow in health and disease[J]. Prog Retin Eye Res, 2008, 27(3): 284-330.
[10]	张栩. 基于代谢组学的2型糖尿病及其微血管并发症的中医证候生物学评价研究[D]. 成都：成都中医药大学，2017.
[11]	Bourne RRA, Stevens GA, White RA, et al. Causes of vision loss worldwide, 1990—2010: a systematic analysis[J]. The Lancet Global Health, 2013, 1(6): e339-e349.
[12]	Xu Y, Wang L, He J. Prevalence and control of diabetes in Chinese adults[J]. JAMA, 2013, 310: 948-959.
[13]	Yau J, Rogers S, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy[J]. Diabetes Care, 2012, 35(3): 556-564.
[14]	段俊国，廖品正，吴烈，等. 中药复方芪明颗粒治疗糖尿病视网膜病变双盲双模拟随机对照多中心临床研究[J]. 成都中医药大学学报，2006，29(2)：1-5.
[15]	李洪超，许扬扬. 芪明颗粒治疗糖尿病视网膜病变的疗效及经济性评价[J]. 药品评价，2014，11(2)：33-39.
[16]	章林慧，吴永江，谢秀琼. 正交实验法优选芪明颗粒提取工艺的研究[J]. 时珍国医国药，2008，19(9)：2168-2169.
[17]	黄菁，王丽波，刘俐利. 羟苯磺酸钙联合芪明颗粒治疗对非增殖期糖尿病视网膜病变患者脉络膜以及血清支链氨基酸、细胞因子的影响[J]. 海南医学院学报，2016，22(18)：2202-2204.
[18]	冯海江，周和定，宋文慧. 芪明颗粒联合血栓通胶囊治疗糖尿病视网膜病变的临床研究[J]. 中国中医药科技，2015，22(3)：255-256.
[19]	董如娇，陈芳，赵霞，等. 全视网膜光凝联合药物治疗糖尿病视网膜病变的临床观察[J]. 中国中医眼科杂志，2015，25(2)：114-117.
[20]	宋剑涛. 芪明颗粒治疗糖尿病视网膜病变随机、阳性药对照、多中心临床研究[D]. 成都：成都中医药大学，2004.
[21]	吴建国. 芪明颗粒治疗中、重度非增生性糖尿病视网膜病变的临床研究[D]. 北京：中国中医科学院，2011.
[22]	中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2017年版)[J]. 中华糖尿病杂志，2018，10(1)：4-67.
[23]	蹇文渊. 芪明颗粒治疗糖尿病视网膜病变的单病例随机对照试验研究[D]. 成都：成都中医药大学，2013.
[24]	陈新. 芪明颗粒对糖尿病微血管病变眼肾损害的影响[D]. 成都：成都中医药大学，2013.
[25]	曾果，刘刚，刘晖，等. 芪明颗粒对单纯型糖尿病视网膜病变患者视网膜功能的影响[J]. 国际眼科杂志，2015，15(3): 495-498.
[26]	Behl T, Kotwani A. Chinese herbal drugs for the treatment of diabetic retinopathy[J]. J Pharm Pharmacol, 2017, 69(3): 223-235.
[27]	Christine A, Schmidt MHH. The role of microglia in diabetic retinopathy: inflammation, microvasculature defects and neurodegeneration[J]. Int J Mol Sci, 2018, 19(1): 110.
[28]	曹平. 糖尿病微血管并发症视网膜血管管径的变化及芪明颗粒干预的影响[D]. 成都：成都中医药大学，2016.
[29]	刘路宏，廖品正，段俊国，等. 芪明对实验性糖尿病大鼠视网膜胰岛素样生长因子-1的影响[C]. 南宁：第七次全国中医糖尿病学术大会，2003：4.
[30]	Stefansson E. Ocular oxygenation and the treatment of diabetic retinopathy[J]. Surv Ophthalmol, 2006, 51: 364-380.
[31]	Bahram K, Kim F, Hilary T. Retinal arterial and venous oxygen saturation is altered in diabetic patients[J]. Invest Ophthalmol Vis Sci, 2013, 54: 7103-7106.
[32]	Jorgensen CM, Hardarson SH, Bek T. The oxygen saturation in retinal vessels from diabetic patients depends on the severity and type of vision threatening retinopathy[J]. Acta Ophthalmol, 2014, 92(1): 34-39.
[33]	Man RE, Sasongko MB, Kawasaki R, et al. Associations of retinal oximetry in healthy young adults[J]. Invest Ophthalmol Vis Sci, 2014, 55(3): 1763-1769.
[34]	蹇文渊. 视网膜血管血氧饱和度及管径在病证结合辨证分析中的应用研究[D]. 成都：成都中医药大学，2016.
[35]	Khoobehi B, Firn K, Thompson H, et al. Retinal arterial and venous oxygen saturation is altered in diabetic patients.[J]. Invest Ophthalmol Vis Sci, 2013, 54(10): 7103-7106.
[36]	Nguyen TT, Wang JJ, Islam FM, et al. Retinal arteriolar narrowing predicts incidence of diabetes: the Australian Diabetes, Obesity and Lifestyle (AusDiab) Study[J]. Diabetes, 2008, 57(3): 536-539.
[37]	Steel DH, Habib MS, Al-Diri B, et al. The association between retinal vascular geometry changes and diabetic retinopathy and their role in prediction of progression: an exploratory study[J]. BMC Ophthalmol, 2014, 14: 89.

项目	动脉血氧饱和度					静脉血氧饱和度
项目	颞上	鼻上	鼻下	颞下	平均值	颞上	鼻上	鼻下
眼数(只)	25	29	29	23	31	27	28	30
治疗前	99.44±6.27	102.58±6.85	101.59±8.34	98.50±8.99	101.12±6.54	63.77±7.90	67.28±8.59	66.52±8.07
治疗后12周	98.75±8.08	100.96±8.44	100.67±8.58	98.47±8.33	100.09±5.95	61.74±7.61	64.38±7.69	61.50±7.20
t值	0.423	1.350	0.617	0.021	1.047	1.261	1.514	3.335
P值	>0.05	>0.05	>0.05	>0.05	>0.05	>0.05	>0.05	<0.05
项目	静脉血氧饱和度		动静脉血氧饱和度差值
项目	颞下	平均值	颞上	鼻上	鼻下	颞下	平均值
眼数(只)	25	31	23	27	28	21	31
治疗前	62.22±11.11	63.18±7.07	35.78±7.87	35.24±7.04	34.68±9.87	37.80±11.89	37.93±6.50
治疗后12周	60.48± 6.59	60.16±5.21	37.21±9.64	36.80±8.07	38.93±9.49	37.91± 8.67	39.93±4.04
t值	1.025	2.482	-0.907	-0.870	-2.182	0.127	-2.259
P值	>0.05	<0.05	>0.05	>0.05	<0.05	>0.05	<0.05

项目	动脉血氧饱和度					静脉血氧饱和度
项目	颞上	鼻上	鼻下	颞下	平均值	颞上	鼻上	鼻下
眼数(只)	25	29	29	23	31	27	28	30
治疗前	99.44±6.27	102.58±6.85	101.59±8.34	98.50±8.99	101.12±6.54	63.77±7.90	67.28±8.59	66.52±8.07
治疗后12周	98.75±8.08	100.96±8.44	100.67±8.58	98.47±8.33	100.09±5.95	61.74±7.61	64.38±7.69	61.50±7.20
t值	0.423	1.350	0.617	0.021	1.047	1.261	1.514	3.335
P值	>0.05	>0.05	>0.05	>0.05	>0.05	>0.05	>0.05	<0.05
项目	静脉血氧饱和度		动静脉血氧饱和度差值
项目	颞下	平均值	颞上	鼻上	鼻下	颞下	平均值
眼数(只)	25	31	23	27	28	21	31
治疗前	62.22±11.11	63.18±7.07	35.78±7.87	35.24±7.04	34.68±9.87	37.80±11.89	37.93±6.50
治疗后12周	60.48± 6.59	60.16±5.21	37.21±9.64	36.80±8.07	38.93±9.49	37.91± 8.67	39.93±4.04
t值	1.025	2.482	-0.907	-0.870	-2.182	0.127	-2.259
P值	>0.05	<0.05	>0.05	>0.05	<0.05	>0.05	<0.05

项目	动脉管径					静脉管径
项目	颞上	鼻上	鼻下	颞下	平均值	颞上	鼻上	鼻下
眼数(只)	25	29	29	23	31	27	28	30
治疗前	131.08±21.50	118.52±21.68	106.03±21.37	128.22±22.69	119.70±14.39	172.07±34.81	142.29±29.31	146.97±39.43
治疗后12周	120.24±20.21	115.59±17.72	107.38±19.25	129.48±19.96	117.30±11.66	158.37±39.57	150.03±29.24	150.23±38.39
t值	2.776	0.888	-0.360	-0.330	1.269	1.524	-1.076	-0.576
P值	<0.05	>0.05	>0.05	>0.05	>0.05	>0.05	>0.05	>0.05
项目	静脉管径		动静脉管径比值
项目	颞下	平均值	颞上	鼻上	鼻下	颞下	平均值
眼数(只)	25	31	23	27	28	21	31
治疗前	170.28±40.26	157.78±20.09	0.77±0.15	0.87±0.28	0.77±0.23	0.76±0.18	0.77±0.10
治疗后12周	165.16±32.82	155.06±20.02	0.81±0.22	0.79±0.19	0.75±0.22	0.79±0.20	0.77±0.13
t值	0.729	0.594	-0.501	1.532	0.435	-1.276	-0.098
P值	>0.05	>0.05	>0.05	>0.05	>0.05	>0.05	>0.05

项目	动脉管径					静脉管径
项目	颞上	鼻上	鼻下	颞下	平均值	颞上	鼻上	鼻下
眼数(只)	25	29	29	23	31	27	28	30
治疗前	131.08±21.50	118.52±21.68	106.03±21.37	128.22±22.69	119.70±14.39	172.07±34.81	142.29±29.31	146.97±39.43
治疗后12周	120.24±20.21	115.59±17.72	107.38±19.25	129.48±19.96	117.30±11.66	158.37±39.57	150.03±29.24	150.23±38.39
t值	2.776	0.888	-0.360	-0.330	1.269	1.524	-1.076	-0.576
P值	<0.05	>0.05	>0.05	>0.05	>0.05	>0.05	>0.05	>0.05
项目	静脉管径		动静脉管径比值
项目	颞下	平均值	颞上	鼻上	鼻下	颞下	平均值
眼数(只)	25	31	23	27	28	21	31
治疗前	170.28±40.26	157.78±20.09	0.77±0.15	0.87±0.28	0.77±0.23	0.76±0.18	0.77±0.10
治疗后12周	165.16±32.82	155.06±20.02	0.81±0.22	0.79±0.19	0.75±0.22	0.79±0.20	0.77±0.13
t值	0.729	0.594	-0.501	1.532	0.435	-1.276	-0.098
P值	>0.05	>0.05	>0.05	>0.05	>0.05	>0.05	>0.05

Please choose a citation manager

Content to export